Pacira agreed to a cash sale at $36.50 per share, giving shareholders a set payment if it closes. Enough shares must be tendered and regulators must clear the deal, but the offer favors Pacira shareholders.
For Pacira shareholders, the agreement sets a cash amount for each share if the sale is completed. It gives the company a defined path to a change in ownership. The sale still depends on enough shares being offered and regulatory clearance. Those requirements could stop it, but the stated cash payment supports a favorable reading for Pacira.
Viatris agreed to buy Pacira for $36.50 per share, subject to tender and regulatory conditions. The filing gives no expected gains, costs, or funding details, so it does not show a clear change to Viatris's business outlook.
Follow Pacira BioSciences, Inc. (PCRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PCRX